<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124189</url>
  </required_header>
  <id_info>
    <org_study_id>GRN163L CP04-151</org_study_id>
    <nct_id>NCT00124189</nct_id>
  </id_info>
  <brief_title>Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)</brief_title>
  <official_title>A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geron Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geron Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in&#xD;
      treating patients with refractory or relapsed chronic lymphoproliferative disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imetelstat Sodium (GRN163L) is a telomerase template antagonist with in vitro and in vivo&#xD;
      activity in a variety of tumor model systems. Telomerase is an enzyme that is active&#xD;
      primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition&#xD;
      of telomerase may result in antineoplastic effects. High telomerase levels and short telomere&#xD;
      lengths correlate with other markers of poor prognosis in patients with chronic&#xD;
      lymphoproliferative disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or recommended phase II dose of GRN163L in patients with relapsed or refractory chronic lymphoproliferative disease</measure>
    <time_frame>First 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK and PD</measure>
    <time_frame>Measured in the first 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Lymphoproliferative Diseases</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRN163L</intervention_name>
    <description>Weekly intravenous infusion</description>
    <arm_group_label>open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Chronic lymphoproliferative disease with related biology or similar clinical pattern&#xD;
             to B-Cell Leukemia (CLL)including: small lymphocytic lymphoma (SLL), T cell&#xD;
             prolymophocytic leukemia (T-PLL), B cell prolymphocytic leukemia (B-PLL), mantle cell&#xD;
             lymphoma or other non-Hodgkins lymphoma in leukemic phase (peripheral blood&#xD;
             circulating malignant cells present), Waldenstrom's macroglobulinemia&#xD;
&#xD;
          -  Must have relapsed from or be refractory to prior therapeutic regimens&#xD;
&#xD;
          -  Patients with CLL or SLL must have received at least one prior purine analogue-based&#xD;
             chemotherapy regimen (eg, fludarabine, pentostatin or cladribine)&#xD;
&#xD;
          -  If previously treated with an anthracycline, anthracenedione, or trastuzumab, must&#xD;
             have left ventricular ejection fraction &gt; 50%&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy 3 months or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Active 2nd malignancy or history of another malignancy within 2 years, except:treated,&#xD;
             non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a&#xD;
             or b prostate cancer&#xD;
&#xD;
          -  Chemotherapeutic agents within 4 weeks prior to study&#xD;
&#xD;
          -  High dose CTX with stem cell support within 6 months prior to study&#xD;
&#xD;
          -  Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study&#xD;
&#xD;
          -  Immunotherapy or biological response modifiers within 4 weeks prior to study&#xD;
&#xD;
          -  Systemic hormonal therapy within 4 weeks prior to study&#xD;
&#xD;
          -  Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study&#xD;
&#xD;
          -  Radiotherapy within 4 weeks prior to study&#xD;
&#xD;
          -  Active autoimmune disorder&#xD;
&#xD;
          -  Central nervous system or leptomeningeal involvement&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Serious/active infection&#xD;
&#xD;
          -  Surgical procedure within 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Kelsey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Geron Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.geron.com</url>
    <description>Sponsor company web page.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>July 25, 2005</study_first_submitted>
  <study_first_submitted_qc>July 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2005</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>T-cell prolymphocytic leukemia</keyword>
  <keyword>Chronic lymphoproliferative diseases</keyword>
  <keyword>Telomerase</keyword>
  <keyword>Telomerase Inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

